{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:58:28Z","timestamp":1789437508655,"version":"build-2803163510"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the last few years, quality of life (QoL) has become an outcome measure in patients with pituitary diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the available data on QoL impairment evaluated with questionnaires in patients with pituitary diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Critical review of the pertinent literature and pragmatic discussion of available information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Selection of relevant literature from PubMed and WOK, especially from the last 5 years and comprehensive analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>QoL is impaired in all pituitary diseases, mostly in acromegaly and Cushing\u2019s disease (similar to other causes of Cushing\u2019s syndrome), but also in non-functioning pituitary adenomas and prolactinomas, especially in the active phase of the disease. Nevertheless, even after endocrine \u2018cure\u2019, scores tend to be below normative values, indicative of residual morbidity after hormonal control. The presence of hypopituitarism worsens subjective QoL perception, which can improve after optimal substitution therapy, including recombinant human growth hormone, when indicated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>To improve the long-term outcome of pituitary patients, helping them to attain the best possible health, it appears desirable to include subjective aspects captured when evaluating QoL, so that the affected dimensions are identified and if relevant treated. Additionally, being aware that treatment outcome may not always mean complete normalisation of physical and mental issues related to QoL can be a first step to adaptation and conforming to this new status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/eje-17-0041","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T20:20:23Z","timestamp":1490732423000},"page":"R13-R26","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":46,"title":["MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease"],"prefix":"10.1093","volume":"177","author":[{"given":"Susan M","family":"Webb","sequence":"first","affiliation":[{"name":"Hospital Sant PauIIB-Sant Pau, Research Center for Pituitary Diseases, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, and Universitat Aut\u00f2noma de Barcelona (UAB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Crespo","sequence":"additional","affiliation":[{"name":"Hospital Sant PauIIB-Sant Pau, Research Center for Pituitary Diseases, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, and Universitat Aut\u00f2noma de Barcelona (UAB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Santos","sequence":"additional","affiliation":[{"name":"Hospital Sant PauIIB-Sant Pau, Research Center for Pituitary Diseases, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, and Universitat Aut\u00f2noma de Barcelona (UAB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Resmini","sequence":"additional","affiliation":[{"name":"Hospital Sant PauIIB-Sant Pau, Research Center for Pituitary Diseases, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, and Universitat Aut\u00f2noma de Barcelona (UAB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Aulinas","sequence":"additional","affiliation":[{"name":"Hospital Sant PauIIB-Sant Pau, Research Center for Pituitary Diseases, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, and Universitat Aut\u00f2noma de Barcelona (UAB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Valassi","sequence":"additional","affiliation":[{"name":"Hospital Sant PauIIB-Sant Pau, Research Center for Pituitary Diseases, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, and Universitat Aut\u00f2noma de Barcelona (UAB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2017051717301477000_177.1.R13.1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrendo.2016.84","article-title":"The chronic syndromes after previous treatment of pituitary tumours","volume":"12","author":"Romijn","year":"2016","journal-title":"Nature Reviews Endocrinology"},{"key":"2017051717301477000_177.1.R13.2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrendo.2011.39","article-title":"Coping with \u2018cured\u2019 pituitary tumors","volume":"7","author":"Webb","year":"2011","journal-title":"Nature Reviews Endocrinology"},{"key":"2017051717301477000_177.1.R13.3","unstructured":"Schipper H Clinch JJ Olweny CLM. Quality of life studies: definitions and conceptual issues. In Quality of Life Assessments in Clinical Trials, p 16. Ed Spilker B . New York: Raven Press Ltd, 1990."},{"key":"2017051717301477000_177.1.R13.4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1055\/s-2000-8144","article-title":"Emotional disorders in patients with different types of pituitary adenomas and factors affecting the diagnosis process","volume":"108","author":"Flitsch","year":"2000","journal-title":"Experimental and Clinical Endocrinology and Diabetes"},{"key":"2017051717301477000_177.1.R13.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.02951.x"},{"key":"2017051717301477000_177.1.R13.6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0941"},{"key":"2017051717301477000_177.1.R13.7","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s11102-015-0636-7","article-title":"Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies","volume":"18","author":"Andela","year":"2015","journal-title":"Pituitary"},{"key":"2017051717301477000_177.1.R13.8","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008846618880"},{"key":"2017051717301477000_177.1.R13.9","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000375451","article-title":"Quality of life in acromegaly","volume":"103","author":"Webb","year":"2016","journal-title":"Neuroendocrinology"},{"key":"2017051717301477000_177.1.R13.10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0669"},{"key":"2017051717301477000_177.1.R13.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03288.x"},{"key":"2017051717301477000_177.1.R13.12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1375"},{"key":"2017051717301477000_177.1.R13.13","first-page":"78","article-title":"Individual and contextual social-status contributions to psychological well-being","volume":"68","author":"Gray","year":"1983","journal-title":"Sociology and Social Research"},{"key":"2017051717301477000_177.1.R13.14","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199711000-00002"},{"key":"2017051717301477000_177.1.R13.15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/00005650-199907000-00007","article-title":"A determining correspondence between scores on the EQ-5D \u2018thermometer\u2019 and a 5-point categorical rating scale","volume":"37","author":"Badia","year":"1999","journal-title":"Medical Care"},{"key":"2017051717301477000_177.1.R13.16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00462.x"},{"key":"2017051717301477000_177.1.R13.17","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008987922774"},{"key":"2017051717301477000_177.1.R13.18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021792"},{"key":"2017051717301477000_177.1.R13.19","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1210\/jc.2014-2892","article-title":"Ten-year change in quality of life in adults on growth hormone replacement for growth hormone deficiency: an analysis of the hypopituitary control and complications study","volume":"99","author":"Mo","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2017051717301477000_177.1.R13.20","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0005"},{"key":"2017051717301477000_177.1.R13.21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0266"},{"key":"2017051717301477000_177.1.R13.22","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12017"},{"key":"2017051717301477000_177.1.R13.23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2006"},{"key":"2017051717301477000_177.1.R13.24","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-1086"},{"key":"2017051717301477000_177.1.R13.25","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0397"},{"key":"2017051717301477000_177.1.R13.26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0685"},{"key":"2017051717301477000_177.1.R13.27","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ12-0134"},{"key":"2017051717301477000_177.1.R13.28","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/and.12199","article-title":"Impaired emotional state, quality of life and cognitive functions in young hypogonadal men","volume":"46","author":"Lasaite","year":"2014","journal-title":"Andrologia"},{"key":"2017051717301477000_177.1.R13.29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/cen.12435","article-title":"Assessment of quality of life during gonadotrophin treatment for male hypogonadotrophic hypogonadism","volume":"81","author":"Shiraishi","year":"2014","journal-title":"Clinical Endocrinology"},{"key":"2017051717301477000_177.1.R13.30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cen.12701","article-title":"Health-related quality of life in male patients with congenital hypogonadotropic hypogonadism","volume":"83","author":"Varimo","year":"2015","journal-title":"Clinical Endocrinology"},{"key":"2017051717301477000_177.1.R13.31","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01597.x"},{"key":"2017051717301477000_177.1.R13.32","doi-asserted-by":"crossref","unstructured":"Webb SM Resmini E Santos A Badia X. Quality of life in acromegaly and growth hormone deficiency. In Growth Hormone Clinics in Endocrinology and Metabolism, pp 237\u2013250. Eds Ho K LeRoith D . New York: Humana Press, 2011. (doi:10.1007\/978-1-60761-317-6_12)","DOI":"10.1007\/978-1-60761-317-6_12"},{"key":"2017051717301477000_177.1.R13.33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11102-016-0761-y","article-title":"Update on quality of life in patients with acromegaly","volume":"20","author":"Crespo","year":"2016","journal-title":"Pituitary"},{"key":"2017051717301477000_177.1.R13.34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2490"},{"key":"2017051717301477000_177.1.R13.35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1645"},{"key":"2017051717301477000_177.1.R13.36","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0896"},{"key":"2017051717301477000_177.1.R13.37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0669"},{"key":"2017051717301477000_177.1.R13.38","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0533-x"},{"key":"2017051717301477000_177.1.R13.39","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0838"},{"key":"2017051717301477000_177.1.R13.40","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0697"},{"key":"2017051717301477000_177.1.R13.41","doi-asserted-by":"publisher","DOI":"10.1023\/B:PITU.0000004798.27230.ed"},{"key":"2017051717301477000_177.1.R13.42","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ghir.2008.05.002","article-title":"Evaluation of cognitive performance by using P300 auditory event related potentials (ERPs) in patients with growth hormone (GH) deficiency and acromegaly","volume":"19","author":"Tanriverdi","year":"2009","journal-title":"Growth Hormone and IGF Research"},{"key":"2017051717301477000_177.1.R13.43","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0676"},{"key":"2017051717301477000_177.1.R13.44","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02214"},{"key":"2017051717301477000_177.1.R13.45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2671"},{"key":"2017051717301477000_177.1.R13.46","doi-asserted-by":"crossref","unstructured":"Badia X Forsythe A Nelson LM Coles TM McLeod LD Webb SM. Improvements in health-related quality of life in acromegaly with pasireotide LAR and octreotide LAR: results from a large, randomized, double-blind phase III trial. In Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Berlin, Germany, 3\u20137 November 2012. Value in Health 2012 15 A505.","DOI":"10.1016\/j.jval.2012.08.1706"},{"key":"2017051717301477000_177.1.R13.47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1586\/erp.11.12","article-title":"Interpreting patient-reported outcome results: US FDA guidance and emerging methods","volume":"11","author":"McLeod","year":"2011","journal-title":"Expert Review on Pharmacoeconomy Outcomes Research"},{"key":"2017051717301477000_177.1.R13.48","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-1101"},{"key":"2017051717301477000_177.1.R13.49","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1007\/s11136-013-0396-7","article-title":"Mapping CushingQoL scores to EQ-5D utility values using data from the European Registry on Cushing's syndrome (ERCUSYN)","volume":"22","author":"Badia","year":"2013","journal-title":"Quality of Life Research"},{"key":"2017051717301477000_177.1.R13.50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40271-013-0010-7","article-title":"CushingQoL Development Group. Mapping CushingQoL scores onto SF-6D utility values in patients with Cushing\u2019s syndrome","volume":"6","author":"Roset","year":"2013","journal-title":"Patient-Patient centered Outcomes Research"},{"key":"2017051717301477000_177.1.R13.51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40271-013-0012-5","article-title":"Psychometric evaluation of the Cushing\u2019s quality-of-life questionnaire","volume":"6","author":"Nelson","year":"2013","journal-title":"Patient-Patient centered Outcomes Research"},{"key":"2017051717301477000_177.1.R13.52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000355622","article-title":"Tuebingen CD-25 is a sensitive tool to investigate health-related quality of life in Cushing's disease patients in the course of the disease","volume":"98","author":"Milian","year":"2013","journal-title":"Neuroendocrinology"},{"key":"2017051717301477000_177.1.R13.53","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0762"},{"key":"2017051717301477000_177.1.R13.54","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0640"},{"key":"2017051717301477000_177.1.R13.55","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2231"},{"key":"2017051717301477000_177.1.R13.56","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0371"},{"key":"2017051717301477000_177.1.R13.57","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0534"},{"key":"2017051717301477000_177.1.R13.58","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11102-013-0484-2","article-title":"Disease-specific quality of life evaluation and its determinants in Cushing\u2019s syndrome: what have we learnt?","volume":"17","author":"Badia","year":"2014","journal-title":"Pituitary"},{"key":"2017051717301477000_177.1.R13.59","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-1078"},{"key":"2017051717301477000_177.1.R13.60","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0272"},{"key":"2017051717301477000_177.1.R13.61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1530\/EJE-16-0779","article-title":"Affective alterations in patients with Cushing\u2019s syndrome in remission are associated with decreased BDNF and cortisone levels","volume":"176","author":"Valassi","year":"2017","journal-title":"European Journal of Endocrinology"},{"key":"2017051717301477000_177.1.R13.62","doi-asserted-by":"crossref","unstructured":"Santos A Webb SM. Coping with Cushing\u2019s syndrome. The patients\u2019 perspectives. In Cushing\u2019s Disease an Often Misdiagnosed and Not So Rare Disorder, pp 170\u2013185. Ed Laws ER Jr. Amsterdam: Elsevier Academic Press, 2017.","DOI":"10.1016\/B978-0-12-804340-0.00010-3"},{"key":"2017051717301477000_177.1.R13.63","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0889-8529(18)30087-2","article-title":"Cushing\u2019s syndrome from the patient perspective","volume":"23","author":"Gotch","year":"1994","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"key":"2017051717301477000_177.1.R13.64","first-page":"75","article-title":"Health-related quality of life in patients with Cushing's syndrome","volume":"39","author":"Curto","year":"2014","journal-title":"Minerva Endocrinologica"},{"key":"2017051717301477000_177.1.R13.65","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12020-015-0737-0","article-title":"A specific nursing educational program in patients with Cushing's syndrome","volume":"53","author":"Mart\u00ednez-Mombl\u00e1n","year":"2015","journal-title":"Endocrine"},{"key":"2017051717301477000_177.1.R13.66","first-page":"536","article-title":"Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing\u2019s disease","volume":"6","author":"van der Pas","year":"2012","journal-title":"Pituitary"},{"key":"2017051717301477000_177.1.R13.67","doi-asserted-by":"publisher","DOI":"10.1002\/hec.4730020305"},{"key":"2017051717301477000_177.1.R13.68","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11102-012-0425-5","article-title":"Evaluation of depression, quality of life and body image in patients with Cushing\u2019s disease","volume":"16","author":"Alcalar","year":"2013","journal-title":"Pituitary"},{"key":"2017051717301477000_177.1.R13.69","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0512"},{"key":"2017051717301477000_177.1.R13.70","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0308"},{"key":"2017051717301477000_177.1.R13.71","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11102-008-0091-9","article-title":"Quality of life in women with microprolactinoma treated with dopamine agonists","volume":"11","author":"Cesar de Oliveira Natiato","year":"2008","journal-title":"Pituitary"},{"key":"2017051717301477000_177.1.R13.72","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0259"},{"key":"2017051717301477000_177.1.R13.73","first-page":"104","article-title":"Update in prolactinomas","volume":"68","author":"Kars","year":"2010","journal-title":"Netherlands Journal of Medicine"},{"key":"2017051717301477000_177.1.R13.74","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.8.2706"},{"key":"2017051717301477000_177.1.R13.75","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2742"},{"key":"2017051717301477000_177.1.R13.76","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0003"},{"key":"2017051717301477000_177.1.R13.77","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2265.2012.04449.x","article-title":"Current treatment protocols can offer a normal or near normal quality of life in the majority of patients with non-functioning pituitary adenomas","volume":"78","author":"Capatina","year":"2013","journal-title":"Clinical Endocrinology"},{"key":"2017051717301477000_177.1.R13.78","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.1400957.x"},{"key":"2017051717301477000_177.1.R13.79","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02118.x"},{"key":"2017051717301477000_177.1.R13.80","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0836"},{"key":"2017051717301477000_177.1.R13.81","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/cen.12967","article-title":"Health-related quality of life in patients treated for non-functioning pituitary adenomas during the years 2000\u20132010","volume":"84","author":"Karppinen","year":"2016","journal-title":"Clinical Endocrinology"},{"key":"2017051717301477000_177.1.R13.82","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11102-016-0707-4","article-title":"The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary","volume":"19","author":"Andela","year":"2016","journal-title":"Pituitary"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/177\/1\/R13.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1530\/EJE-17-0041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T11:10:31Z","timestamp":1676373031000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/177\/1\/R13\/6655246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":82,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/eje-17-0041","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}